Frank A. Post

Frank A. Post

Auto-generated profile, based on publicly available information

Frank A. Post

King's College Hospital NHS Foundation Trust, London, UK

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2019 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PSPaul E Sax
Paul E Sax
KEKristine M Erlandson
Kristine M Erlandson
JLJordan E Lake
Jordan E Lake
GMGrace A Mccomsey
Grace A Mccomsey
COChloe Orkin
Chloe Orkin
JKJohn R Koethe
John R Koethe
Background: Initiation of antiretroviral therapy (ART) often leads to weight gain. While some of this weight gain may be an appropriate return-to-health effect, excessive increases in weight may lead to obesity. We sought to explore factors associated with weight gain in several randomized comparative clinical trials of ART initiation. Methods: We performed a pooled analysis of weight gain in 8 randomized controlled clinical trials of treatment-naive people living with human immunodeficiency virus (HIV) initiating ART between 2003 and 2015, comprising >5000 participants and 10 000 person-years of follow-up. We used multivariate modeling to explore relationships between demographic factors, HIV disease characteristics, and ART components and weight change following ART initiation. Results: Weight gain was greater in more recent trials and with the use of newer ART regimens. Pooled analysis revealed baseline demographic factors associated with weight gain including lower CD4 cell count, higher HIV type 1 RNA, no injection drug use, female sex, and black race. Integrase strand transfer inhibitor use was associated with more weight gain than were protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs), with dolutegravir and bictegravir associated with more weight gain than elvitegravir/cobicistat. Among the NNRTIs, rilpivirine was associated with more weight gain than efavirenz. Among nucleoside/nucleotide reverse transcriptase inhibitors, tenofovir alafenamide was associated with more weight gain than tenofovir disoproxil fumarate, abacavir, or zidovudine. Conclusions: Weight gain is ubiquitous in clinical trials of ART initiation and is multifactorial in nature, with demographic factors, HIV-related factors, and the composition of ART regimens as contributors. The mechanisms by which certain ART agents differentially contribute to weight gain are unknown.

31 July 2010 in AIDS
Verified
Journal Article
Closed access
TWTanya Welz
Tanya Welz
KCKate Childs
Kate Childs
FIFowzia Ibrahim
Fowzia Ibrahim
MPMary Poulton
Mary Poulton
CTChris B Taylor
Chris B Taylor
FPFrank A Post
Frank A Post
Objective(s): To identify factors (including exposure to specific antiretroviral drugs) associated with severe vitamin D deficiency (VDD) in HIV-infected individuals and to explore the effects of severe VDD and antiretroviral drug exposure on serum alkaline phosphatase (ALP) as surrogate marker of bone turnover. Design: Cross-sectional survey of vitamin D status among HIV-infected patients attending for routine clinical care at a large London HIV clinic. Methods: Severe VDD was defined as 25(OH)D levels of less than 10 μg/l (<25 nmol/l). Multivariate logistic regression analysis was used to identify factors associated with severe VDD and upper quartile ALP levels. Results: Vitamin D levels were measured in 1077 patients and found to be suboptimal in 91%. One-third of patients had severe VDD. Black ethnicity, sampling in winter, nadir CD4 cell count less than 200 cells/μl, and exposure to combination antiretroviral therapy were associated with severe VDD. In analyses restricted to patients on combination antiretroviral therapy, current efavirenz use was significantly associated with severe VDD [adjusted odds ratio 2.0 (95% confidence interval 1.5–2.7)]. Current tenofovir [adjusted odds ratio 3.5 (95% confidence interval 2.3–5.2)] and efavirenz use [adjusted odds ratio 1.6 (95% confidence interval 1.02–2.4)], but not severe VDD [odds ratio 1.1 (0.8–1.5)], were associated with increased bone turnover (upper quartile ALP). Conclusion: Efavirenz was associated with severe VDD, a condition associated with multiple adverse health outcomes, and efavirenz and tenofovir with increased ALP. The clinical significance of these findings requires further investigation, given the widespread use of efavirenz and tenofovir in first-line combination antiretroviral therapy.

28 October 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
OGon behalf of the POPPY study group
on behalf of the POPPY study group
DFDavide De Francesco
Davide De Francesco
JUJonathan Underwood
Jonathan Underwood
FPFrank A. Post
Frank A. Post
Jaime Vera RojasJaime Vera Rojas
Jaime Vera Rojas
CSCaroline Anne Sabin
Caroline Anne Sabin
The reported prevalence of cognitive impairment (CI) varies widely in cohorts of people living with HIV (PLWH); this may partly be due to the use of different diagnostic criteria. Agreement between diagnostic criteria of CI, the optimal definition to use, and associations with patient-reported cognitive symptoms have not been fully investigated. Two hundred ninety PLWH aged >50 years and 97 matched negative controls completed a detailed assessment of cognitive function and three questions regarding cognitive symptoms. Age- and education-adjusted test scores (T-scores) determined if subjects met the following definitions of CI: Frascati, global deficit score (GDS) and the multivariate normative comparison (MNC) method. PLWH were more likely than controls to meet each definition of CI (ORs were 2.17, 3.12 and 3.64 for Frascati, GDS and MNC, respectively). Agreement of MNC with Frascati and GDS was moderate (Cohen’s k = 0.42 and 0.48, respectively), whereas that between Frascati and GDS was good (k = 0.74). A significant association was found between all the three criteria and reporting of memory loss but not with attention and reasoning problems. The 41 (14 %) PLWH meeting all the three criteria had the lowest median global T-score (36.9) and highest rate of symptom reporting (42 %). Different CI criteria show fair diagnostic agreement, likely reflecting their ability to exclude CI in the same group of individuals. Given the lower overall cognitive performance and higher rates of symptom reporting in those meeting all three criteria of CI, further work assessing this as a definition of CI in PLWH is justified.

15 April 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FPFrank A. Post
Frank A. Post
LCLucy J. Campbell
Lucy J. Campbell
LHLisa Hamzah
Lisa Hamzah
LCLisa Collins
Lisa Collins
RJRachael Jones
Rachael Jones
PEPhilippa J. Easterbrook
Philippa J. Easterbrook
Background. Human immunodeficiency virus (HIV)—associated nephropathy (HIVAN) is an important cause of end-stage renal disease among African American

15 July 2008 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JRJennifer Roe
Jennifer Roe
LCLucy J. Campbell
Lucy J. Campbell
FIFowzia Ibrahim
Fowzia Ibrahim
BHBruce M. Hendry
Bruce M. Hendry
FPFrank A. Post
Frank A. Post
Background. The clinical epidemiology of acute renal failure (ARF) in human immunodeficiency virus (HIV)-infected patients remains poorly defined.

27 May 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KCKate Childs
Kate Childs
FPFrank A Post
Frank A Post
CNClaire Norcross
Claire Norcross
ZOZoë Ottaway
Zoë Ottaway
EHElizabeth Hamlyn
Elizabeth Hamlyn
CTChris Taylor
Chris Taylor
Kate Childs, M.D, Frank A Post, M.D, Ph.D, Claire Norcross, M.D, Zoë Ottaway, M.D, Elizabeth Hamlyn, M.D, Killian Quinn, M.D, Ph.D, Thomas Juniper, M.D, Chris T